MedTrace Logo

Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]

NCT04645212 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 23

Last updated 2026-02-10

No results posted yet for this study

Summary

ADVM-022-07 is an observational long-term extension (OPTIC-EXT) study assessing safety and efficacy of ADVM-022 gene therapy product, in participants with neovascular, or exudative (wet), age-related macular degeneration (nAMD).

Conditions

Interventions

BIOLOGICAL

ADVM-022

Long term follow-up of subjects that received ADVM-022

Sponsors & Collaborators

  • Adverum Biotechnologies, Inc.

    lead INDUSTRY

Principal Investigators

  • OPTIC-EXT Medical Monitor · Adverum Biotechnologies, Inc.

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-14
Primary Completion
2030-06-26
Completion
2030-06-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04645212 on ClinicalTrials.gov